Arcus Biosciences, Inc. logo RCUS - Arcus Biosciences, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 15
HOLD 3
SELL 0
STRONG
SELL 0
| PRICE TARGET: $40.00 DETAILS
HIGH: $47.00
LOW: $23.00
MEDIAN: $42.50
CONSENSUS: $40.00
UPSIDE: 63.87%

Stock News

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company's Board of Directors granted 2 new employees options to purchase a total of 9,150 shares of the Company's common stock at an exercise price per share of $23.83, which was the closing pric.

Oct 09, 2026 12:35 PM • businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 21,200 shares of the Company's common stock at an exercise price per share of $26.39, which was the closing.

Sep 24, 2026 12:35 PM • businesswire.com
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City. The event will highlight new data from the ARC-20 platform study, which is evaluating casdatif.

Sep 22, 2026 04:30 AM • businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company's common stock at an exercise price per share of $29.06, which was the.

Sep 09, 2026 12:35 PM • businesswire.com
Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2026 Biotech Back to School Conference Date: Wednesday, September 9th, 2026 Location: New York, NY Format: Fireside chat &amp.

Aug 26, 2026 12:05 PM • businesswire.com
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $28.72, which was the.

Aug 11, 2026 12:35 PM • businesswire.com
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. "Our recent publication in Nature demonstrated our commitme.

Aug 05, 2026 12:05 PM • businesswire.com
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of  Arcus Biosciences, Inc. ( NYSE : RCUS) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

Jul 29, 2026 06:26 PM • globenewswire.com (Hide legal announcements)
Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 12,600 shares of the Company's common stock at an exercise price per share of $29.73, which was.

Jul 27, 2026 12:35 PM • businesswire.com
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical supply agreement with AVEO Oncology, an LG Chem company (“AVEO”). Under the agreement, the companies will evaluate casdatifan, Arcus's investigational small-molecule HIF-2α inhibitor, in combination with tivozan.

Jul 22, 2026 12:35 PM • businesswire.com
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne.

Jul 22, 2026 12:30 PM • businesswire.com
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, August 5th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline updates for the quarter ended June 30th, 20.

Jul 21, 2026 12:05 PM • businesswire.com

Price Targets